Drug development timelines and what FDA approval actually requires

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Researchers, investors, patients, and anyone trying to understand how long the path from early research to an approved psychedelic drug actually takes, and what the FDA requires along the way.

The short answer

The path from early laboratory research to FDA approval of a new drug typically takes over a decade and costs hundreds of millions of dollars, with most drug candidates failing before they reach approval. The FDA requires a sponsor to show, through a defined sequence of studies, that a drug is safe and effective for the intended use at the proposed dose in the intended population. For psychedelic drugs, the path follows the same general sequence as any other drug, with additional questions about trial design, the therapy component, and the administration setting that the agency has engaged with specifically. The fastest psychedelic programs to reach Phase 3 did so in roughly a decade from early trials. An approved psychedelic drug remains at least several years away for the programs currently in late-stage development.

The preclinical stage

Before any human is dosed in a clinical study, a sponsor must develop sufficient animal data to support human exposure. Preclinical work includes pharmacology studies, dose-range finding, and toxicology studies in animal models. The goal is to establish a starting dose that is reasonably safe for the first human study and to identify the risks that will need monitoring. For psychedelics, much of the basic pharmacology has been in the scientific literature for decades, but a sponsor seeking an IND for a specific formulation or indication must compile and submit the data relevant to that specific program. IND applications and FDA oversight of psychedelic clinical trials covers the IND that follows.

Phase 1: safety in healthy volunteers or patients

Phase 1 studies test the drug in a small number of people, usually healthy volunteers, to establish safety, tolerability, and pharmacokinetics — how the drug moves through the body, how it is metabolized, and how long it stays active. Phase 1 for psychedelics often includes people with the target condition rather than healthy volunteers, because the subjective effects of the drug make healthy-volunteer studies less informative and the population of interest is defined. The COMPASS psilocybin program began Phase 1 studies in this way. Phase 1 is not designed to show efficacy.

Phase 2: dose-finding and early efficacy signals

Phase 2 studies test the drug in a larger group of people with the target condition to explore efficacy signals and refine the dose. They are typically randomized and controlled, comparing the drug to a placebo or an active comparator, but they are usually not large enough to provide the definitive evidence the FDA needs for approval on their own. A positive Phase 2 result supports moving to Phase 3 and, for some programs, a Breakthrough Therapy designation that gives the sponsor more FDA interaction during development. COMPASS received Breakthrough Therapy designation for COMP360 in treatment-resistant depression.

Phase 3: the confirmatory trials

Phase 3 studies are the trials the FDA relies on most heavily for an approval decision. They are larger, randomized, and controlled, and they are designed to provide substantial evidence of effectiveness and to characterize the safety profile in the intended population. The FDA generally expects two adequate and well-controlled Phase 3 studies for a new drug application, though it can accept one under some circumstances. For psychedelic-assisted therapies, Phase 3 design has raised specific questions about blinding — participants and raters often know whether the drug was given — and the FDA has engaged with sponsors on how to design studies that produce reliable results despite that challenge. MAPS’s MDMA program completed two Phase 3 studies and submitted an NDA; the FDA issued a Complete Response Letter in 2024 citing concerns about the trial data and requesting an additional study. COMPASS’s COMP360 Phase 3 program has shown positive results in two studies, COMP005 and COMP006, and the company is moving toward a rolling NDA submission in late 2026.

The New Drug Application

After Phase 3, a sponsor assembles the full clinical development package into a New Drug Application and submits it to the FDA. The NDA includes the preclinical data, all clinical trial data, the chemistry, manufacturing and controls information, and the proposed prescribing information. The FDA determines whether the submission is complete enough to review, and if so, assigns a review classification — standard, which carries a ten to twelve month review goal, or priority, which carries a six month goal for drugs that address serious conditions. The agency can issue an approval, a Complete Response Letter requesting more information, or, rarely, a refusal to file. The MAPS CRL and the COMPASS rolling NDA are the two most closely watched submissions in the psychedelic space as of mid-2026.

The therapy component is a regulatory question, not just a design choice

Psychedelic drug programs typically pair drug administration with a structured therapeutic protocol. The FDA must decide what it is approving: the drug alone, or the drug in combination with a specific therapy that is required for safety or effectiveness. If the agency determines that the therapy is a required component, it may impose Risk Evaluation and Mitigation Strategy requirements, training mandates for providers, or restrictions on the settings where the drug can be administered. What that approval looks like in practice determines how many patients can access the drug after approval and how the commercial model works.

Post-approval obligations

FDA approval is not the end of regulatory oversight. Post-approval, the sponsor may be required to conduct additional studies on specific safety questions, to report adverse events through the agency’s pharmacovigilance system, and to maintain the manufacturing and quality systems the NDA describes. A sponsor that receives accelerated approval — based on a surrogate endpoint rather than direct clinical benefit — must complete post-approval confirmatory trials. The label can be updated as new data emerge.

Where the leading programs stand

As of mid-2026, COMPASS Pathways is preparing a rolling NDA submission for COMP360 in treatment-resistant depression on the strength of two positive Phase 3 studies and Breakthrough Therapy designation. GH Research is in Phase 3 with GH001, a 5-MeO-DMT program for treatment-resistant depression. MAPS’s MDMA program, following the 2024 CRL, is in the process of planning an additional study. Approval for any of these programs, if it comes, would be followed by a DEA rescheduling proceeding before the drug could be commercially distributed, adding time between approval and patient access.

When public information may be enough

The FDA’s drug approval regulations, guidance documents, and the agency’s published correspondence with psychedelic sponsors are largely public. The agency’s website covers the IND and NDA process in detail, and it publishes approval letters and summary review documents. A researcher or investor can learn the structure of the development path and the requirements at each stage from those sources.

When you should speak with a lawyer or regulatory professional

The decisions that shape a development program — the trial design, the IND strategy, the pre-NDA meetings with the FDA, and the management of the therapy component question — require regulatory professionals who know both the general drug development process and the agency’s specific engagement with psychedelic programs. Regulatory missteps are expensive to correct and can delay approval by years. An investor entering this space should have regulatory counsel review the development status of any company under consideration before committing.

You might also want to read

This article provides general legal information, not legal advice, and does not create an attorney-client relationship. Psychedelic law differs by state and changes over time. Consult a licensed attorney in your jurisdiction before acting on anything described here.